Evogene Ltd. — Investor Presentation 2026

Jun 16, 2026

G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant’s Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☑ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

---

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

99.1 Evogene Investor Presentation.

---

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD.
(Registrant)

Date: June 16, 2026

By: /s/ Ofer Haviv
Ofer Haviv
Chief Executive Officer

---

Exhibit 99.1

evgene

REAL-WORLD INNOVATION

REAL-WORLD INNOVATION

Al-first driven discovery platform for multi-parameter small-molecule generation

June 16 2026

---

FORWARD LOOKING STATEMENT

This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd. (the "Company"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, pipeline, as well as our capabilities and technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, the current war between Israel and Hamas and any further adverse impact that it may have on economic activity in Israel due to the calling up of a large number of reserve soldiers or the incurrence of debt to pay for the high cost of the war, and any accompanying future uncertainties for the security of the Company's operations in southern Israel, as well as those additional factors described in greater detail in Evogene's Annual Report on Form 20-F and in other reports Evogene files with and furnishes to the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract or commitment relating thereto or to the securities of the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

1 evogene

---

EVOGENE PIONEERS REAL-WORLD INNOVATION

Using a proprietary generative AI engine, we generate novel and highly potent small molecules, optimized across multiple-parameters, for the pharmaceutical and ag-chemical industries

evogene

---

OUR STORY

PIONEERING IN PHARMA

Growing number of collaborations for a diverse pipeline of drug candidates

GEN AI ENGINE

ChemPass AI™ – computational engine for the generation & optimization of small molecules

REVOLUTIONIZING AG

Proven strategic collaborations driving our ag-chem pipeline

evogene

---

THE DISCOVERY & OPTIMIZATION CHALLENGE

GENERATE THE RIGHT CANDIDATES TO REACH THE MARKET

FIXO MA	FIELD, NICAL	CLINICAL
AB	SAFETY & ENVIRONMENT	FIELD TESTING

5 evogene

---

DIVERSE NOVEL CHEMICAL STRUCTURES & MULTI-PARAMETER CHALLENGE

The challenge - generate diverse small molecules with novel chemical structures that satisfy all required parameters defining the desired product, while proactively balancing multiple, often competing, criteria

CURRENT MAIN LIMITATIONS:

• Confined to a limited chemical space
• Lacks capability to perform multi-parameter optimization simultaneously

evogene

---

1 evogene

CHEMPASS AI™

BREAKING CHEMICAL SPACE LIMITATION & MULTI-PARAMETER CHALLENGE

NOVEL CHEMICAL STRUCTURE - DRUG-LIKE, SYNTHESIZABLE MOLECULES

Our AI engine generates novel compounds that are synthesizable and active, while accessing unexplored chemical space and creating new IP opportunities

MULTI-PARAMETER OPTIMIZATION

Multiple-parameters optimized to project-specific chemical, biological, and physical constraints, increasing probability of success

CHEMOTYPE DIVERSITY - DE-RISKING DOWNSTREAM DEVELOPMENT

A broad and diverse scope of development candidates, that meet the defined product specifications

---

CHEMPASS AI™ - THREE STEPS TO SUCCESS

evogene

• NW TA is small-embryonic drug development stands for Benign-Male-Test-Angles

---

EVOGENE'S UNIQUE OFFERING – NOVEL CHEMISTRY THAT WORKS

POINTHIT™ & ACTIVESEARCH™ - INTELLIGENCE: UNIQUE DATASET CREATION

• Both POINTHIT™ & ACTIVESEARCH™ explore ultra-large vendor libraries - 70B molecules
• POINTHIT™ utilizes virtual screening to generate a diverse range of chemotypes from the earliest stages of the discovery process
• ACTIVESEARCH™ is an analogue search-engine coupled with QSAR to optimize DMTA cycles

Deep understanding of the biology and chemistry underlying the target product

LEADOP GPT™ - THE MAGIC: NOVEL MOLECULE GENERATION

• In-house built AI engine trained on curated 38B molecules database (Google Cloud collaboration #1)
• Generation of molecules that satisfy multiple project-specific parameters simultaneously (Google Cloud collaboration #2)
• Precision generation of novel bioactive molecules tailored to target product criteria, eliminating inefficient traditional filtering

evogene

---

10
evogene
* Based on company's calculation.

TECHNOLOGICAL COLLABORATIONS WITH GOOGLE CLOUD

FROM GENERATIVE MODELS TO AUTONOMOUS DISCOVERY

FIRST COLLABORATION – FIRST-IN-CLASS FOUNDATION MODEL

Successful completion of a proprietary generative AI model for novel molecular product candidates addressing multiple parameters, based on 38 billion molecular structures, delivered 90% precision compared to approx. 30% in traditional GPT models*.

SECOND COLLABORATION – ADVANCED AI AGENTS INTEGRATION

Integration of AI agents into ChemPass AI™ using Google Cloud Agent Platform to produce data for multi-parameter modeling, accelerate design-make-test-analyze cycles, and scale the discovery of patentable small molecules with stronger potential for commercial success across pharmaceutical and agricultural pipelines. Initiated Feb. 2026

This expanded collaboration with Evogene demonstrates the power of integrating cutting-edge artificial intelligence into scientific research. By leveraging our technology to deploy advanced AI agents, we are enabling Evogene to automate and scale their complex discovery workflows. This foundation accelerates the speed and precision of identifying small molecules, further cementing Evogene's role as a leader in next-generation molecular design for the pharmaceutical and agricultural industries

DOAZ MAOZ, MANAGING DIRECTOR, GOOGLE CLOUD ISRAEL (10.02.2026)

Google Cloud

---

CHEMPASS AI™ - GENERATES CANDIDATES FOR COMMERCIAL SUCCESS

evogene

---

BUSINESS STRATEGY

CO-DEVELOPMENT - CAPTURE THE VALUE OF CHEMPASS AI™

Unlock the full potential of ChemPass AI™ through strategic collaborative partnerships, accelerating innovation in small-molecule drug and agrochemical development

PARTNERING WITH PHARMA, AG-CHEMICAL & BIOTECH COMPANIES

that complement our capabilities, enabling groundbreaking innovations that benefit both parties

MAXIMUM POTENTIAL, MINIMUM RISK

12 evogene

---

CHEMPASS AI™ WORKFLOW

13 evogene

---

HARNESSING THE POWER OF CHEMPASS AI FOR REAL-WORLD INNOVATION

PHARMA DIVISION – DRUGS

AG DIVISION* – AG-CHEMICALS

COLLABORATIONS

systasy
Neutrophil-Derived Inflammatory Diseases

UNRAVEL BIO SCIENCES
Demyelination Disorders

CUP
Queensland University of Technology
Lung Cancer

TEL-AIR 2128713199
UNIVERSITY 2124135
Metabolic Disease

COLLABORATIONS

CORTEVA™ geraclence
Herbicides

INTERNAL PIPELINE
Wheat Blotch

AG DIVISION* – Operations in this field are conducted through our subsidiary, AgPlenus.

evogene

---

OUR STORY

PIONEERING IN PHARMA

Growing number of collaborations for a diverse pipeline of drug candidates

GEN AI ENGINE

ChemPass AI®- computational engine for the generation & optimization of small molecules

REVOLUTIONIZING AG

Proven strategic collaborations driving our ag-chem pipeline

15 evogene

---

PHARMA DIVISION

GROWING OPPORTUNITY IN AI-DRUG DISCOVERY

SMALL MOLECULES

Account for 58% of total pharmaceutical market ($1,344B)

AI-based candidates in pipeline >60% 150% CAGR in last 3 years

Discovery market expected to reach ~$190B by 2034

16 evogene © NSAT Value Chain Insights 25 Science Direct 35 Precedence Research

---

PHARMA DIVISION

AI-FIRST COMPOUNDS UNDER DEVELOPMENT

The indicated data are for March 2025 *

Data includes both in-house and partner programs, data is NOT exhaustive, it reflects only information disclosed by companies on their websites.

evogene

---

PHARMA DIVISION

POTENTIAL COLLABORATORS & BUSINESS DEVELOPMENT STRATEGY

POTENTIAL PARTNERS	UNMET NEEDS	COMMON COLLABORATION PROFILE	TIMELINE
ACADEMIA/
SMALL BIOTECH	1. Rapid computational generation of molecules
with high probability of success for novel targets
2. Composition of matter patents	A strategic partnership to co-develop a novel drug
asset, generate shared IP and/or commercialization
rights while accelerating the path to clinical
development	Initiated
end of 2025
MID-BIG SIZE BIOTECH/
MID SIZE PHARMA	1. Rapid computational generation of molecules
with high probability of success for novel targets
2. Computational generation of novel chemotypes
with improved patent positions and introduction
of broad chemical diversity	Joint discovery and optimization of novel drug assets.
Evogene will receive R&D and milestone-based
payments, and royalties	Mid term
(2027+)
GLOBAL PHARMA	1. Generation of novel chemotypes with improved
patent positions and introduction of broad
chemical diversity
2. Computational solutions for non-trivial targets	1. Joint discovery and optimization of novel drug
assets. Evogene will receive R&D and milestone-
based payments, and royalties
2. Evogene delivers a dedicated computational
technology solution for a specific R&D challenge in
exchange for upfront, R&D and milestone-based
payments	Long term
(2028+)

evogene

---

PHARMA DIVISION

DIVERSIFIED DRUG DISCOVERY PIPELINE – CURRENT STATUS

INDICATION	PROGRAM	HIT ID	HIT-TO-LEAD	LEAD OPTIMIZATION	PRE-CLINICAL	IND	PARTNER
COLLABORATIONS
Oncology	EVG-O311						Undisclosed
Metabolism*	EVG-M410
Immunology	EVG-I110						systasy
Neurology	EVG-N210						UNRAVEL
BIO SCIENCES
Oncology	EVG-O310						Queensland University of Technology
INTERNAL PIPELINE
Undisclosed	EVG-R510						evogene

• Non-graduates Larged

evogene

---

PHARMA DIVISION

COLLABORATION WITH A LEADING ACADEMIC INSTITUTE (UNDISCLOSED)

NOVEL THERAPIES FOR BREAST CANCER TREATMENT AND LONGEVITY

• Target: novel key mechanism linked to cancer cell survival, migration and therapy resistance
• Global breast cancer therapy market is estimated at $30-37B annually, with aggressive forms representing 10-15% of the cases, with an estimated market of $1-5B
• Combines ChemPass AI™ with expertise in spatial genomics and genome stability
• Designed to generate novel small-molecule candidates for aggressive form of breast cancer

BINDING SITE AND LIGAND OF TARGET

20 evogene

---

POINTHIT™ - SUPERIOR HIT RATES OF HIGHLY POTENT MOLECULES

42 molecules identified with outstanding results*

• 43% of tested considered candidate inhibitors
• 19% of tested compounds have nM efficacy

"We used to screen thousands of compounds to get hits, with ChemPass AI this is not required. Out of 42 compounds, 18 (43%) are inhibitors, and 8 (19%) are potential candidates." PI

evogene

• Intermediate analysis

---

PHARMA DIVISION

COLLABORATION WITH PROF. EHUD GAZIT, TAU, TEL-AVIV, ISRAEL

NOVEL THERAPEUTIC MODALITY FOR METABOLIC DISEASES

• Target: molecular self-assembly metabolites that underlie metabolic conditions
• Addressable Gout therapeutics market is evaluated at -$3B*
• Combines ChemPass AI™ with unique biological research in molecular self-assembly biology
• Creates opportunities for novel therapeutics addressing the cause of disease rather than symptomatic treatment

> "We are excited to join forces with Evogene in this groundbreaking endeavor. By integrating our fundamental understanding of molecular self-assembly with Evogene's cutting-edge AI-driven drug design platform, we have a unique opportunity to develop novel therapeutics that specifically target these pathological processes and ultimately improve treatment for patients."

SCANNING ELECTRON MICROSCOPY OF CRYSTALS
FORMED BY THE SELF-ASSEMBLY OF A METABOLITE

• Costa-Braun, A. & Grisau, F. (2023). Biomolecules, 13(12), 1769.

22 evogene
http://www.quadrinsensur.tu.com/industry-analysis/qual-therapeutics-market

---

PHARMA DIVISION

COLLABORATION WITH PROF. EHUD GAZIT, TAU, TEL-AVIV, ISRAEL

NOVEL THERAPEUTIC MODALITY FOR METABOLIC DISEASES – CHEMPASS AI™ RESULTS

INTERMEDIATE ANALYSIS OF INITIAL 15 MOLECULES

• 33% of tested compounds reach activity threshold
• 2 molecules outperformed positive control

NEXT STEP

• Ongoing testing of additional molecules for hit identification

evogene

---

OUR STORY

PIONEERING IN PHARMA

Growing number of collaborations for diverse drug targets

GEN AI ENGINE

ChemPass AI®– computational engine for the generation & optimization of small molecules

REVOLUTIONIZING AG

Proven strategic collaborations driving our ag-chem pipeline

24 evogene

---

agPlenus

EVRGENE'S SUBSIDIARY

~$88B GROWING MARKET WITH PLENTY OF ROOM FOR INNOVATION

UNMET NEEDS

1. Increase of pest resistance & regulatory requirements
2. Urgent need for new Modes of Action (MoAs)
3. Decreased rate in discovery of new pesticides due to lack of innovation

evogene

Company calculation based on: © Monitor Intelligence © Fortune Business Insights © Data Bridge

---

agPlenus
EVOGENE'S SUBSIDIARY

LEADING CROP PROTECTION COMPANIES

• BASF
• BAYER
• CORTEVA
  agriscience
• FMC
• syngenta
• ADAMA
• Goyan
• nufarm
• UPL
• Dperag
• KUREHA
• NIPPON SODA CO.,LTD.

POTENTIAL DISCOVERY AND OUTLICENSE PARTNERS

evogene

---

agPlenus

EVRÆINE'S SUBSIDIARY

CURRENT CROP PROTECTION PIPELINE

PROGRAM	INDICATION	HIT ID	HIT-TO-LEAD	LEAD OPTIMIZATION	SAFETY AND ENVIRONMENTAL	FIELD TESTING	PARTNER
COLLABORATIONS
Herbicide	APCO-12			Stage confidential			CORTEVA agriplenus
INTERNAL PIPELINE
Fungicide	APTF1/APTF4						agPlenus

27 evogene

---

agPlenus

EVRÆNET'S SUBSIDIARY

INTERNAL PIPELINE WHEAT BLOTCH

DISRUPTING A $1.28 PROBLEM AT RECORD SPEED

• 70% of EU fungicide usage in wheat is for Wheat Blotch
• EU market alone >$1.28 annually
• Widespread resistance to current top products ('Strobilurins') with 2025 sales of $4.768¹

APTF-1 PRESENTS STRONG POTENTIAL FOR REAL-WORLD INNOVATION

• Shows clear concentration-dependent antifungal efficacy
• Ongoing optimization to enhance potency
• 18 months from target to optimized hit

evogene © Global Growth Insights

---

AgPlenus
EVOGENE'S SUBSIDIARY

END-TO-END PROCESS – NOVEL, HIGHLY POTENT, OPTIMIZED MOLECULES

TARGET PROTEIN

New MOA - no available crystallographic structure with limited computational data

29 evogene

• Performed by AgPlenus, Evogene's wholly owned subsidiary

---

EVOGENE - LOOKING FORWARD

PHARMA DIVISION - DRUGS

• Progress in existing pipeline
• New collaborations with biotech companies and academic institutions
• Building relationships with pharmaceutical companies
• Evaluation of projects for an internal pipeline

AG DIVISION* - AG-CHEMICALS

• Progress in existing pipeline
• New collaborations with ag-chem companies
• Evaluation of projects for expanding internal pipeline

ADDITIONAL TECH COLLABORATIONS TO MAINTAIN OUR COMPETITIVE ADVANTAGE

30 evogene

AG DIVISION* – Operations in this field are conducted through our subsidiary, AgPlenus.

---

31
evogene

NOVEL, DRUG-LIKE, SYNTHESIZABLE MOLECULES

MULTI-PARAMETER OPTIMIZATION

DE-RISKING DOWNSTREAM DEVELOPMENT

We generate highly potent and novel small molecules, optimized across multiple-parameters, for the pharmaceutical and ag-chemical industries

evogene

PIONEERING IN PHARMA

Growing number of collaborations addressing diverse drug targets for the benefit of human health

REVOLUTIONIZING AG

Proven impact in Agriculture. Computational chemistry drives real-world agricultural impact

GENERATING REAL-WORLD INNOVATION

---

evogene

Creating
REAL-WORLD
INNOVATION
for a better future